Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07158437 | Phase 1 Study of SL-325 in Healthy Volunteers | PHASE1 | ACTIVE NOT_RECRUITING | 72 | — | — | Sep 18, 2025 | Jul 1, 2026 | Apr 30, 2026 | 1 | United States |
Incidence and severity of treatment-emergent adverse events
| Arm | Type | Description |
|---|---|---|
| SAD: SL-325 | EXPERIMENTAL | Participants will receive a single dose of SL-325 in escalating dose cohorts |
| SAD: Placebo | PLACEBO_COMPARATOR | Participants will receive a single dose of placebo (normal saline) |
| MAD: SL-325 | EXPERIMENTAL | Participants will receive a three doses of SL-325 in escalating dose cohorts |
| MAD: Placebo | PLACEBO_COMPARATOR | Participants will receive a three doses of placebo (normal saline) |
| Name | Type | Description |
|---|---|---|
| SL-325 | BIOLOGICAL | DR3 blocking antibody |
| Placebo (Normal Saline) | OTHER | Normal saline |
Inclusion Criteria: 1. Provide signed informed consent 2. 18-55 years of age, inclusive, at the time of signing the informed consent form 3. Body mass index of 18-32 kg/m2, inclusive, and a total body weight \> 50 kg 4. Laboratory values within normal limits or any abnormalities deemed not clinical...